Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal

Lung cancer (non small cell, EGFR mutation positive) - afatinib: evaluation report

1 Pre Meeting Briefing

3a Manufacturer submission from Boehringer Ingelheim

3b Patient Access Scheme

4a NICE request to the manufacturer for clarification

4b Manufacturer response to request for clarification

5a Roy Castle Lung Cancer Foundation statement

5b Royal College of Pathologists statement

5c Royal College of Physicians statement

6a Jesme Fox patient expert declaration

6b Clive Mulatero clinical specialist declaration

7a Evidence Review Group Report

7b Evidence Review Group Report Erratum

8 Factual accuracy check of the Evidence Review Group Report

9 Evidence Review Group Report Addendum

If you are unable to download this document, you may need to save to your device and open.